about
Zooprophylaxis or zoopotentiation: the outcome of introducing animals on vector transmission is highly dependent on the mosquito mortality while searchingCan mutation and selection explain virulence in human P. falciparum infections?Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewA research agenda for malaria eradication: modelingA Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014)High yield production process for Shigella outer membrane particlesSafety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adultsThe sequence of a 200 kb portion of a Plasmodium vivax chromosome reveals a high degree of conservation with Plasmodium falciparum chromosome 3.Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data.Ten families of variant genes encoded in subtelomeric regions of multiple chromosomes of Plasmodium chabaudi, a malaria species that undergoes antigenic variation in the laboratory mouse.A quantitative slot blot assay for host cell protein impurities in recombinant proteins expressed in E. coli.Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malariaHuman immunity and the design of multi-component, single target vaccines.Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult MaliansPhase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children.Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malariaThe role of variant surface antigens on malaria-infected red blood cells.Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malariaA protective monoclonal antibody recognizes a linear epitope in the precursor to the major merozoite antigens of Plasmodium chabaudi adami.Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers.Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum.Vaccines against poverty.Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutantsTransport of an Mr approximately 300,000 Plasmodium falciparum protein (Pf EMP 2) from the intraerythrocytic asexual parasite to the cytoplasmic face of the host cell membraneProgress and challenges for malaria vaccines.Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar TyphiBiochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.Stochastic simulation of endemic Salmonella enterica serovar Typhi: the importance of long lasting immunity and the carrier state.Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar TyphimuriumSustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex.Relationship between antibody susceptibility and lipopolysaccharide O-antigen characteristics of invasive and gastrointestinal nontyphoidal Salmonellae isolates from Kenya.An O antigen capsule modulates bacterial pathogenesis in Shigella sonnei.Progress in the development of recombinant and synthetic blood-stage malaria vaccines.Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer.Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidatesMonoclonal Antibodies of a Diverse Isotype Induced by an O-Antigen Glycoconjugate Vaccine Mediate In Vitro and In Vivo Killing of African Invasive Nontyphoidal Salmonella.Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titerDecreased membrane deformability in Melanesian ovalocytes from Papua New Guinea.
P50
Q24804822-6254212E-B4B1-43AB-A741-5D778B9F26F3Q24806349-AD86B67F-0558-4220-B6C3-738BC94F8005Q26700078-C1640860-C904-4ABD-91BC-0990E43011D8Q28476808-8EC9FE66-E30D-4065-9D51-AE87FBE1D982Q28555213-BD4A825D-7409-4292-86FE-F569926C34D7Q28728768-B193DCD2-CF66-4498-8815-6F7C47F6B546Q28744376-5AFFD5CD-B4F3-4F9D-8F34-624413C09373Q30776459-51D64C35-D554-4FCD-8DF9-B36A7CDB295FQ30982324-7C2ADFF3-E826-40E8-9B66-C915EE429685Q31144715-374840B0-5D96-4761-BB7A-BDCCC332C32AQ33222694-C5E8FC4F-380A-4F1D-9BD0-68656FD194D6Q33281394-445C2F55-A707-4CA1-9AEE-D83DF8E3CB57Q33297012-BC158207-F573-44F8-866C-A1D64B2F47C5Q33302903-12CAA5B2-F78B-46F4-BAC6-FB3CC760E2B4Q33319552-027ED6D8-A553-4870-8989-929BD7B40A34Q33350210-3CCF901D-D0D9-4A45-A072-7DC9E7163DDAQ33359552-8229318C-F787-4BAE-806C-616F9C0AE767Q33746986-8485F5D9-5741-498A-8253-CA23A2B445C6Q33788306-CA31B920-C369-4E73-9B63-C8E2143D4B58Q33858336-A58189E2-BA8A-4B34-B692-DD5E0A0A1401Q34003999-A11D5FCE-7D2D-4F98-8F2F-9AE36E37000DQ34075564-6A3641B2-E7A3-4DAF-86D0-5FD590CB8498Q34110755-D022EBCF-ADB6-4C9A-8CE7-0D915EB5051EQ34119892-9E41F4BF-6EC7-4F00-8E9B-14BE606E9E40Q34138990-5F0DE8F5-3495-476D-AFF9-21C78F389B8BQ34394551-E507BF7C-B400-4CB0-A61B-E8235788FD0EQ34521010-14E8FA92-242E-49B9-B957-8FF93AA3088AQ34739155-5EDE60FB-1A26-40DD-9C74-F459CA5E03F8Q34940333-57896492-9776-41E4-ACA6-B2D202E7C534Q34989762-C4FF327D-5D9E-4A97-B3B6-B62AE91BAAE5Q35098175-1C690ED0-7A9C-4219-A25D-65A0700BDCD9Q35132063-1D87CAF2-2C25-4FE4-AE1F-6D45AA43544BQ35154889-2D312FA7-4835-49AA-BFEA-245EAD77B5B7Q35202321-CFF8D109-A542-4839-9D7A-0C3253C6E465Q35541797-402D1F07-A139-41B9-9491-4F1C29C36BBDQ35634133-0A80F43B-A85E-42A0-A0D8-FA9FC417BCD9Q35925379-687DE45D-E84F-4095-90CF-62D29D64C502Q35947429-0682B006-63C6-4E9A-AC57-F8FD8376E16DQ35982771-2753E832-723A-4BAC-A562-ED8652D30E16Q36210680-0B1861DC-DA02-479C-B643-B7218120A595
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Allan Saul
@ast
Allan Saul
@en
Allan Saul
@es
Allan Saul
@nl
Allan Saul
@sl
type
label
Allan Saul
@ast
Allan Saul
@en
Allan Saul
@es
Allan Saul
@nl
Allan Saul
@sl
prefLabel
Allan Saul
@ast
Allan Saul
@en
Allan Saul
@es
Allan Saul
@nl
Allan Saul
@sl
P1053
I-6968-2013
P106
P21
P2798
P31
P3829
P496
0000-0003-0665-4091